US3621LQ1099 - Common Stock
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights ...
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference...
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024...
G1 Therapeutics (GTHX) stock sank 53% Tuesday, the day after the company issued an update for a Phase 3 study of its breast cancer drug trilaciclib. Read more here.
NextEra Energy stock is on the move Tuesday after Evercore ISI initiated coverage of NEE shares with a bull rating and price target.
Nvidia stock is a hot topic among NVDA traders on Tuesday after the company's shares got a new $850 price target from UBS analysts.
Polished.com stock is sliding lower on Tuesday as investors in POL react to the company missing a debt payment and other dangers.
G1 Therapeutics stock is down on Tuesday after the company provided GTHX investors with an update on a Phase 3 clinical trial.
Pre-market stock movers are a hot topic on Tuesday and we're diving into all of the biggest winners and losers this morning!
Shares of G1 Therapeutics (GTHX) plunged 36% in post-market trading after the company said the independent data monitoring committee overseeing a pivotal Phase
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC...
G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference. ...
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference...
January 2024 Inducement Grants...
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent...
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...